A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population
← catalyst calendarNCT06724848 · readout in 428 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
850estimated
Sites
14
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-05 | actual | When the study began enrolling |
| Primary completion | 2027-10-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-21 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COPD
Primary outcomes
what the primary-completion date above is the date OFMedical History
measured At Baseline
Occupation
measured At Baseline
Birth Status
measured At Baseline
Place of residence
measured At Baseline
Smoking history and status
measured At Baseline to week 56
Family history
measured At Baseline
Exacerbation/respiratory history and event
measured At Baseline to week 56
COPD related HRU
measured At Baseline to week 56
SGRQ
measured At Baseline to week 56
CAT
measured At Baseline to week 56
MARS-5 (only applicable for COPD cohort)
measured At Baseline to week 56
Variables in COPD related medication, changes in medication
measured At Baseline to week 56
FEV1 %
measured At Baseline to week 56
FEV1 /FVC
measured At Baseline to week 56
Forced Osc
measured At Baseline to week 56
FEF25-75
measured At Baseline to week 56
DLCO
measured At Baseline to week 56
LAAinsp-950%
measured At Baseline to week 56
LAAexp-856%
measured At Baseline to week 56
WA%
measured At Baseline to week 56
Inflammatory differentials and counts in blood and BALF
measured At Baseline to week 56
Inflammatory cell infiltration
measured At Baseline to week 56
MUC5B/MUC5AC
measured At Baseline to week 56
IL-33/ST2 complex
measured At Baseline to week 56
IL-33
measured At Baseline to week 56
Air trapping index
measured At Baseline to week 56
hsCRP
measured At baseline to week 56
Transcriptomic test in nasal, bronchial brushings, biopsies and BALF asmples
measured At baseline to week 56
Proteomic test in blood, sputum, BALF and NLF samples
measured At baseline to week 56
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed